US Bancorp’s Estrella Immunopharma ESLA Stock Holding History

US Bancorp’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.8K	Buy	20,000 +3,096	+18%	+$4.05K	﹤0.01%	3187
2026 Q1	$17.9K	Buy	+16,904	New	+$19.4K	﹤0.01%	3162

Other funds holding ESLA

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

US Bancorp's ESLA Position: Q2 2026 in Review

US Bancorp increased its Estrella Immunopharma (ESLA) stake by 18% in Q2 2026, buying an estimated $4.05K and bringing the position to 20,000 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3187.

US Bancorp first reported a position in ESLA in Q1 2026 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

US Bancorp held 20,000 shares of Estrella Immunopharma worth $20.8K as of Q2 2026.
US Bancorp bought 3,096 Estrella Immunopharma shares in Q2 2026, an estimated $4.05K.
Estrella Immunopharma made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3187 holding.
US Bancorp first reported a position in Estrella Immunopharma in Q1 2026 and has held it in 2 quarters since.
15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.